尽管收入增长,但Mirum制药公司在缺少收入估计数和降低全年指导之后,股票下跌。 Mirum Pharmaceuticals shares fell after missing earnings estimates and lowering full-year guidance despite revenue growth.

在报告季度每股损失0.11美元后,Mirum制药公司(MIRM)股份在星期四下跌,估计损失0.13美元,尽管年年收入增加49.8%,达到1.4893亿美元。 Mirum Pharmaceuticals (MIRM) shares dropped on Thursday after reporting a quarterly loss of $0.11 per share, missing estimates by $0.13, despite a 49.8% year-over-year revenue increase to $148.93 million. 该公司的2026年全年收入指导为63 000万美元至65 000万美元,低于预期,没有概述近期盈利途径。 The company’s full-year 2026 revenue guidance of $630M–$650M fell short of expectations, and no near-term path to profitability was outlined. 一些分析家提出稀有肝病治疗的进展,提高了价格目标,但股票交易量低于平均水平,跌至94.97美元。 While some analysts raised price targets, citing progress in rare liver disease treatments, the stock traded down to $94.97 with lower-than-average volume. 内幕人士在90天内出售股票435万美元,分析员预计2026年每股损失1.43美元。 Insiders sold $4.35 million in shares over 90 days, and analysts expect a $1.43 per share loss for 2026.